Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Immunotherapy Firm Releases Data Showing Treatment Potential Against Sepsis

Recently presented results from Enlivex Therapeutics' Phase 1b study in sepsis and their implications are reviewed in an H.C. Wainwright & Co. report. In a June 1 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Enlivex Therapeutics Ltd.'s ...
Streetwise Reports | June 4, 2020 |

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

The compelling aspects of this life sciences story are presented in a Dawson James report. In a Jan. 28 research note, analyst Jason Kolbert reported that Dawson James Securities increased its target price on Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) to $15 pe...
Streetwise Reports | February 3, 2020 |

Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares

Solid Biosciences' shares are up by more than 40% today after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. Duchenne muscular dystrophy (DMD) research firm Solid Biosciences ...
Streetwise Reports | August 20, 2019 |

'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs

The next steps for each of the programs are outlined in a Dawson James Securities report. In an Aug. 14 research note, Dawson James Securities analyst Jason Kolbert reported that Soligenix Inc. (SNGX:NASDAQ) "is now focused on the two pivotal programs, i...
Streetwise Reports | August 22, 2019 |

Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data

Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer. Clinical-stage biopharmaceutical company Mersana Therapeuti...
Streetwise Reports | May 28, 2020 |

Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's

How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note. In a Dec. 2 research note, Dawson James Securities analyst Jason Kolbert purported that Anavex Life Sciences Corp.'s (AVXL:NASDAQ) ANAV...
Streetwise Reports | December 11, 2019 |

New Data Could Drive Use of Pancreatic Cancer Early Detection Test

The recent results and their implications are provided in an H.C. Wainwright & Co. report. In an Oct. 25 research note, H.C. Wainwright & Co. analyst Yi Chen reported that newly compiled data support the clinical utility of Interpace Diagnostics Group Inc.'s (IDXG:NA...
Streetwise Reports | October 30, 2019 |

Cassava Shares Rise on Updated Phase 2b Alzheimer's Drug Trial Data

Shares of Cassava Sciences traded 70% higher after the firm provided updates from its Phase 2b study of PTI-125 for use in treating Alzheimer' disease. Clinical-stage biotechnology company Cassava Sciences Inc. (SAVA:NASDAQ) , which focuses on neurodegenerative di...
Streetwise Reports | June 4, 2020 |

Moderna Shares Rise 25% on Positive Phase 1 Coronavirus Vaccine Trial Data

Shares of Moderna Inc. traded higher, setting a new 52-week high price, after the firm reported positive interim results in its Phase 1 study of mRNA Vaccine (mRNA-1273) against SARS-CoV-2. Clinical-stage biotechnology company Moderna Inc. (MRNA:NASDAQ) , which fo...
Streetwise Reports | May 19, 2020 |

Three COVID-19 Patients Treated with PLX Cells

Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report. In a March 30 research note, Dawson James Securities analyst Jason Kolbert reported that three high-risk COVID-19 pati...
Streetwise Reports | April 2, 2020 |
1 2 3 4 5 6 7 8 9 10 ...